natgillin/translations-raw huggingface dataset:
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3%; IZ: 24,3%, 57,5%) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2%; IZ: 6,5%, 28,3%).
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Primarni opazovani dogodki so bili navzočnost kompozita (zaradi infarkta zamašene arterije) na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
Pharmacogenetics: Based on literature data, patients with genetically reduced CYP2C19 function have lower systemic exposure to the active metabolite of clopidogrel and diminished antiplatelet responses, and generally exhibit higher cardiovascular event rates following myocardial infarction than do patients with normal CYP2C19 function (see section 5.2).
Farmakogenetika: Podatki iz literature kažejo, da imajo bolniki z genetsko zmanjšano funkcijo CYP2C19 manjšo sistemsko izpostavljenost aktivnemu presnovku klopidogrela in manjše antitrombocitne odzive; delež kardiovaskularnih dogodkov po miokardnem infarktu je pri teh bolnikih na splošno večji kot pri bolnikih z normalnim delovanjem CYP2C19 (glejte poglavje 5.2).
There was no excess in major bleeds with clopidogrel + ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery (4.4% clopidogrel + ASA vs. 5.3% placebo + ASA).
Število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v sedmih dneh po koronarni premostitveni operaciji pri bolnikih, ki so zdravljenje prekinili več kot pet dni pred kirurškim posegom (klopidogrel in ASA: 4,4%%; placebo in ASA 5,3%%).
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Klopidogrel se in vitro in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85% presnovkov v obtoku), druga pa z več encimi citokroma P450.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+ASA, and 6.3% for placebo + ASA.
Pri bolnikih, ki so se zdravili do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6%% za klopidogrel in ASA in 6,3%% za placebo in ASA.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%.
V stanju dinamičnega ravnovesja je bila povprečna raven zaviranja z odmerkom 75 mg na dan 40- do 60%.
• if you suffer from severe liver disease.
• če imate hudo jetrno obolenje.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5-15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25%%) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4).
• Ledvična okvara Terapevtske izkušnje pri bolnikih z ledvično okvaro so omejene (glejte poglavje 4.4).
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Zaviralci agregacije trombocitov preprečujejo to zlepljanje in s tem zmanjšajo možnost za nastanek krvnih strdkov (proces se imenuje tromboza).
Patients were randomized to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Bolniki so bili naključno razdeljeni v skupine, ki so jemale 75 mg klopidogrela na dan ali 325 mg ASA na dan, spremljali so jih od 1 leto do 3 leta.
28 film-coated tablets 28x1 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets 56x1 film-coated tablets 84 film-coated tablets 84x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets
28 filmsko obloženih tablet 28x1 filmsko obložena tableta 30 filmsko obloženih tablet 30x1 filmsko obložena tableta 50 filmsko obloženih tablet 50x1 filmsko obložena tableta 56 filmsko obloženih tablet 56x1 filmsko obložena tableta 84 filmsko obloženih tablet 84x1 filmsko obložena tableta 90 filmsko obloženih tablet 90x1 filmsko obložena tableta 100 filmsko obloženih tablet 100x1 filmsko obložena tableta
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
Pri zdravljenju tega stanja vam je zdravnik v zamašeno ali zoženo arterijo morda moral vstaviti stent (žično opornico), da bi žilo tako razširil in obnovil pretok krvi.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to reduced metabolism.
Alel CYP2C19*1 ustreza polno funkcionalni presnovi, medtem ko alela CYP2C19*2 in CYP2C19*3 ustrezata zmanjšani presnovi.
The most common side effect (affects 1 to 10 patients in 100) reported with Clopidogrel Teva Generics B.V. is bleeding.
Najpogostejši neželeni učinek (pojavi se pri 1 do 10 od 100 bolnikov), o katerem so poročali med zdravljenjem z zdravilom Klopidogrel Teva Generics B.V.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Zdravilo vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
V študiji CAPRIE je bila pri bolnikih, ki so se zdravili s klopidogrelom ali z ASA, skupna incidenca vseh krvavitev 9,3%%.
Published frequencies for the common CYP2C19 phenotypes and genotypes are listed in the table below.
Objavljene pogostnosti pogostih fenotipov in genotipov CYP2C19 so navedene v spodnji preglednici.
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel.
Farmakokinetika digoksina ali teofilina se ob sočasnem jemanju klopidogrela ni spremenila.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects')
• morate zdravniku takoj povedati, če se pri vas pojavi bolezensko stanje (znano kot tombotična trombocitopenična purpura ali TTP), ki vključuje zvišano telesno temperaturo in modrice pod kožo (pojavijo se kot drobne rdeče pike), nerazložljiva huda utrujenost, zmedenost ter porumenelost kože ali oči (zlatenica) (glejte poglavje »Možni neželeni učinki«);
Propylene glycol
smukec propilenglikol
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Tako kot druge antitrombotike tudi klopidogrel previdno uporabljamo pri bolnikih, pri katerih zaradi poškodbe, kirurškega posega ali drugih patoloških stanj obstaja tveganje za povečano krvavitev, in pri bolnikih, ki so na zdravljenju z ASA, s heparinom, z zaviralci glikoproteina IIb/IIIa ali z nesteroidnimi protivnetnimi zdravili (NSAID), vključno z zaviralci ciklooksigenaze-2 (COX-2).
This could potentially lead to increased plasma levels of medicinal products such as phenytoin and tolbutamide and the NSAIDs, which are metabolised by Cytochrome P450 2C9.
To lahko povzroči povečano plazemsko koncentracijo fenitoina in tolbutamida ter nesteroidnih protivnetnih zdravil, ki se presnavljajo s citokromom P450 2C9.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Aktivni presnovek klopidogrela selektivno zavira vezavo adenozin-difosfata (ADP) na njegov trombocitni receptor P2Y12 in nadaljnjo aktivacijo glikoproteinskega kompleksa GP IIb/IIIa z
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišane srčne encime ali troponin I ali T
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2-oksoklopidogrela.
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
• Z akutnim koronarnim sindromom: Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Študija CURE je vključevala 12.562 bolnikov z akutnim koronarnim sindromom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca) do 24 ur po zadnji epizodi bolečine v prsih ali simptomih, konsistentnih z ishemijo.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see sections 4.4 and 5.2).
Iz previdnosti naj sočasno ne bi uporabljali zdravil, ki zavirajo CYP2C19 (glejte poglavji 4.4 in 5.2).
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
68,7%, nefebrinsko specifične: 31,1%), 89,5% heparin, 78,7% zaviralce adrenergičnih receptorjev beta, 54,7% zaviralce ACE in 63 % statine.
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction.
je večina bolnikov jemala ASA prvih nekaj dni po akutnem MI.
You should specifically tell your doctor if you take - oral anticoagulants, medicines used to reduce blood clotting, - a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, - heparin, or any other medicine used to reduce blood clotting.
Podrobno morate obvestiti svojega zdravnika, če jemljete - peroralne koagulanse, zdravila, ki se uporabljajo za preprečevanje strjevanja krvi, - nesteroidna protivnetna zdravila, običajno za lajšanje bolečih in/ali vnetih sklepov ali mišic,
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
zobca, visoka do nizka raven tveganja, diabetes, potreba po revaskularizaciji, spol, starost, itd), so skladni z rezultati primarne analize.
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Koristi, ki so jih opazili s klopidogrelom, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovinami za zniževanje lipidov, zaviralci adrenergičnih receptorjev beta in zaviralci angiotenzinske konvertaze (ACEI)).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus
(toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozni izpuščaj, urtikarija, ekcem, lihen planus
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups, respectively).
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve majhen in podoben v obeh skupinah (0,6-odstoten v skupini s klopidogrelom in ASA ter 0,5-odstoten v skupini s placebom in ASA).
If you experience prolonged bleeding when taking Clopidogrel Teva Generics B.V.
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Teva Generics B.V.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis
(hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Zlasti post hoc analiza podatkov 2172 bolnikov (17% celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2% zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9% zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
CYP2C19 poor metaboliser status is associated with diminished response to clopidogrel.
• Farmakogenetika Status slabega presnavljalca s CYP2C19 je povezan z manjšim odzivom na klopidogrel.
The incidence of severe cases was 1.4% for clopidogrel and 1.6% for ASA.
Incidenca hujših primerov krvavitev je bila pri klopidogrelu 1,4%%, pri ASA pa1,6%%.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Iz previdnosti naj sočasno ne bi uporabljali zdravil, ki zavirajo CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7%; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3%; IZ: -5,7 do 18,7 /p = 0,258/).
• Severe liver impairment.
• Huda jetrna okvara.
If you become pregnant while taking Clopidogrel Teva Generics B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) - a recent serious injury - a recent surgery (including dental) - a planned surgery (including dental) in the next seven days
- zdravstveno stanje s tveganjem za notranjo krvavitev (rana na želodcu), - krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa), - nedavna huda poškodba, - nedavni kirurški poseg (tudi na zobeh),
As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4).
Zaradi previdnosti se je treba izogniti sočasni uporabi omeprazola ali esomeprazola (glejte poglavje 4.4).
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
(6,6%) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Rare side effect (affects 1 to 10 patients in 10,000): Vertigo.
Redki neželeni učinki (pojavijo se pri 1 do 10 od 10.000 bolnikov): vrtoglavica.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Klopidogrel nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000
Jedro tablete: mikrokristalna celuloza brezvodni koloidni silicijev dioksid krospovidon (vrsta A) makrogol 6000 hidrogenirano ricinusovo olje
Skin and subcutaneous tissue disorders
Bolezni kože in podkožja bulozni dermatitis
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
Okvara jeter Po večkratnem odmerjanju 75 mg klopidogrela na dan 10 dni pri bolnikih s hudo okvaro jeter je bilo zavrtje z ADP izzvane agregacije trombocitov podobno kot pri zdravih preiskovancih.
If you take more Clopidogrel Teva Generics B.V. than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).
ki bi bilo daljše od štirih tednov, v tem okviru niso preučevali (glejte poglavje 5.1).
In CURE, the major bleeding event rate for clopidogrel + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (clopidogrel: 1.9%; placebo: 1.0%).
Tveganje za krvavitve (življenje ogrožajoče, velike, manjše, druge) se je zmanjševalo med preizkušanjem: 0-1 meseca (klopidogrel: 9,6%%; placebo: 6,6%%), 1-3 mesecev (klopidogrel: 4,5%%; placebo: 2,3%%), 3-6 mesecev (klopidogrel: 3,8%%; placebo: 1,6%%), 6-9 mesecev (klopidogrel: 3,2%%; placebo: 1,5%%), 9-12 mesecev (klopidogrel: 1,9%%; placebo:
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
22% (IZ: 8,6, 33,4), 32% (IZ: 12,8, 46,4), 4% (IZ: -26,9, 26,7), 6% (IZ: -33,5, 34,3) in 14% (IZ: -31,6,
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics.
Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z ali brez uporabe trombolitikov.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets-calendar pack)
PRETISNI OMOT (28x1 filmsko obložena tableta - koledarsko pakiranje)
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade ojačenja trombocitne aktivacije s sproščenim ADP.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen.
Na farmakodinamiko klopidogrela tudi ni pomembno vplivalo sočasno jemanje fenobarbitala ali estrogena.
Several polymorphic CYP450 enzymes activate clopidogrel.
Klopidogrel aktivira več polimorfnih encimov CYP450.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni opazovani dogodek je bil opažen pri 15,0% bolnikov v skupini s klopidogrelom in 21¸7% bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7% in 36% zmanjšanje verjetnosti v prid klopidogrela (95% IZ od 24% do 47%; p<0,001) v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (začetni odmerek 300 mg, nato 75 mg/dan, n=6.259) ali skupino, ki je prejemala placebo (n=6.303), oboje prejeto v kombinaciji z ASA (75-325 mg enkrat na dan) in drugimi standardnimi terapijami.
Acute liver failure, hepatitis, abnormal liver function test
žolčnika in žolčevodov akutna jetrna odpoved, hepatitis, nenormalni testi jetrne funkcije
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Pri bolnikih z akutnim koronarnim sindromom: Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).